Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04466618 · ClinicalTrials.gov registry record · Phase 3
Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes
A Phase 3 study, sponsored by Adrian Vella.
- Completed
- Registry status
- Phase 3
- Development phase
- 23
- Enrollment target
NCT04466618: Completed Phase 3 study, sponsored by Adrian Vella.
NCT04466618 is a Phase 3 study that has completed, run by Adrian Vella. The registered enrollment target is 23 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04466618, a Phase 3 study, has completed, sponsored by Adrian Vella.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 23 participants
- Enrollment target
Study Summary
GLP-1 is a hormone made by the body that promotes the production of insulin in response to GLP-1 is produced within the islets expressing prohormone convertase 1/3eating. However, there is increasing evidence that this hormone might help support the body's ability to produce insulin when diabetes develops. The purpose of this study is to determine the effect of endogenous GLP-1 secretion on insulin secretion in people with and without type 2 diabetes.
Primary Outcome
Concentrations of glucagon Measured by immunoassay over the -30 to 0 minutes of study. On one study day subjects received saline, on the other exendin-9,39. The infusion commenced at -120 minutes.
Interventions
- BIOLOGICAL Saline
- BIOLOGICAL Exendin-9,39
- BIOLOGICAL Saline + Intralipid/Heparin
- BIOLOGICAL Exendin-9,39 + Intralipid/Heparin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2021-04-15 |
| Est. Completion | 2022-12-31 |
| Phase | Phase 3 |
What the finished NCT04466618 record still lists
NCT04466618 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 4 interventions - of which Saline is the first listed.
NCT04466618 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04466618 about?
NCT04466618 is a clinical study titled "Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes". GLP-1 is a hormone made by the body that promotes the production of insulin in response to GLP-1 is produced within the islets expressing prohormone convertase 1/3eating. However, there is increasing evidence that this hormone might help support the body's ability to produce insulin when diabetes de...
What is the current status of trial NCT04466618?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 23 participants. The study started on 2021-04-15. Estimated completion is 2022-12-31.
What interventions are being tested in trial NCT04466618?
The interventions under investigation include: Saline (BIOLOGICAL), Exendin-9,39 (BIOLOGICAL), Saline + Intralipid/Heparin (BIOLOGICAL), Exendin-9,39 + Intralipid/Heparin (BIOLOGICAL).
Who is sponsoring clinical trial NCT04466618?
This trial is sponsored by Adrian Vella, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04466618's enrollment target sits among peer trials
23 1952nd of 2000 higher than 48 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI